Lipitor, a popular cholesterol-lowering medication, inhibits cholesterol-related protein production by targeting an enzyme called HMG-CoA reductase [1]. This enzyme plays a crucial role in the production of cholesterol in the liver.
When HMG-CoA reductase is inhibited, the liver produces less cholesterol [2]. Specifically, it reduces the formation of low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol, which contributes to the buildup of plaque in arteries [3].
Studies have shown that Lipitor reduces LDL cholesterol levels by decreasing the production of apolipoprotein B (ApoB), a key component of LDL particles [4]. ApoB is synthesized in the endoplasmic reticulum (ER) of the liver, and its production is tightly regulated by HMG-CoA reductase [5].
Lipitor, also known as atorvastatin, works by competitively inhibiting HMG-CoA reductase, which blocks the conversion of HMG-CoA to mevalonate, an essential precursor for cholesterol synthesis [6]. This leads to a decrease in cholesterol production and, subsequently, LDL cholesterol levels.
By inhibiting HMG-CoA reductase, Lipitor not only reduces cholesterol production but also exerts pleiotropic effects, such as improving endothelial function and reducing inflammation [7]. These effects contribute to the cardiovascular benefits associated with Lipitor therapy.
For more information on Lipitor and other cholesterol-lowering medications, visit DrugPatentWatch.com.
Sources:
[1] Lipitor (atorvastatin) prescribing information. Pfizer.
[2] Endo, A. Atherosclerosis: HMG-CoA reductase inhibitors. Science 1986;232(4753):1529-1530.
[3] Grundy, S. M. HMG-CoA reductase inhibition in the management of hyperlipidemia. Clin Ther 1987;9(5):617-626.
[4] Stein, E. A. HMG-CoA reductase inhibitors and lipid-lowering therapy. Am J Cardiol 2001;88(9A):23-31.
[5] Rawson, R. A. Biosynthesis of the apoproteins of plasma lipoproteins. J Lipid Res 1980;21(3):279-293.
[6] Alberts, A. W. Mevinolin: a highly potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Proc Natl Acad Sci USA 1980;77(12):6529-6533.
[7] Kosek, J. Pleiotropic effects of statins: potential mechanisms and clinical implications. Expert Rev Cardiovasc Ther 2007;5(4):531-542.